Licorice extract which is used as a natural
sweetener has been shown to possess inhibitory effects against
prostate cancer, but the mechanisms responsible are poorly understood. Here, we report a compound,
isoangustone A (IAA) in licorice that potently suppresses the growth of aggressive
prostate cancer and sought to clarify its mechanism of action. We analyzed its inhibitory effects on the growth of PTEN-deleted human
prostate cancer cells, in vitro and in vivo. Administration of IAA significantly attenuated the growth of
prostate cancer cell cultures and xenograft
tumors. These effects were found to be attributable to inhibition of the G1/S phase cell cycle transition and the accumulation of p27(kip1). The elevated p27(kip1) expression levels were concurrent with the decrease of its phosphorylation at
threonine 187 through suppression of CDK2
kinase activity and the reduced phosphorylation of Akt at
Serine 473 by diminishing the
kinase activity of the
mammalian target of rapamycin (mTOR). Further analysis using
recombinant proteins and immunoprecipitated cell lysates determined that IAA exerts suppressive effects against CDK2 and mTOR
kinase activity by direct binding with both
proteins. These findings suggested that the licorice compound IAA is a potent molecular inhibitor of CDK2 and mTOR, with strong implications for the treatment of
prostate cancer. Thus, licorice-derived extracts with high IAA content warrant further clinical investigation for nutritional sources for
prostate cancer patients.